Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 summary

Strategic and pipeline priorities

• Focused on developing T-cell engagers for solid tumors, with all programs acquired externally.

• Three programs target claudin 6, mesothelin, and nectin-4; claudin 6 and mesothelin are in the clinic, nectin-4 entering soon.

• Addressing ADC resistance in solid tumors, aiming to fill the post-ADC treatment gap.

• Exploring protocol amendments to enable less frequent dosing, aligning with recent industry trends.

• Strategic priority to present data and expand into earlier lines and combinations with ADCs.

Claudin 6 program insights

• Claudin 6 is highly selective for tumors, enabling higher dosing and targeting ADC-resistant ovarian cancer.

• Phase 1a data expected in Q2, focusing on platinum-resistant, ADC-exposed ovarian patients.

• High prevalence of claudin 6 in late-line ovarian patients, with 80% positivity and high target density.

• Aiming for a 30% response rate in a population with 5-10% standard of care response.

• Potential for outpatient dosing and every-three-week schedules if safety and PK data support.

Dosing strategies and CRS management

• Industry shift toward longer dosing intervals to reduce T-cell exhaustion and improve efficacy.

• Step dosing and steroid prophylaxis effectively manage CRS, with steroids preferred over IL-6 inhibitors up front.

• Priming doses show biomarker activity even if not inducing responses.

• Protocol amendments planned to enable every-three-week dosing across programs.

• CRS risk is now considered manageable, with focus shifting to on-target, off-tumor liabilities.